Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Cervical cancer ranks among the most prevalent malignancies affecting the female reproductive system. It stands as the second leading cause of cancer-related deaths in women aged 20 to 39. The prognosis for cervical cancer patients, especially those in advanced stages, remains grim. Human papillomavirus (HPV) infects the majority of sexually active individuals at some point in their lives. There exist more than 130 distinct HPV types, with 20 of them associated with cancer. The rates of HPV-related cervical dysplasia are only documented in women. The most frequently encountered HPV strains in invasive cervical cancer are HPV 16 and 18. Risk factors for HPV and cervical cancer encompass factors such as the age at first sexual intercourse, having multiple sexual partners, smoking, herpes simplex infection, HIV infection, co-infection with other genital infections, and the use of oral contraceptives. HPV spreads through skin-to-skin contact, including sexual intercourse, hand-to-genital contact, and oral sex. Over 75 percent of cases are linked to high-risk HPV types 16 and 18. It is crucial to evaluate visible cervical lesions for signs of cervical cancer. Nevertheless, cervical cancer in its early stages usually does not present as an obvious mass and, as mentioned earlier, tends to be asymptomatic.

·       Each year in the United States, about 11,500 new cases of cervical cancer are diagnosed.

 

Thelansis’s “Cervical Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cervical Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Cervical Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Cervical Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Cervical Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Cervical Cancer, Cervical Cancer market outlook, Cervical Cancer competitive landscape, Cervical Cancer market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033